Search

everythinglearnresearchcommunity

for

Search:↓

After a hair transplant, it's advised to stop using RU58841 and minoxidil to avoid irritation, resuming them 25-30 days post-surgery if the scalp is healed. The user is currently using finasteride, minoxidil, and RU58841, but there are concerns about the safety and efficacy of RU58841 in humans.

A user did not respond to finasteride, dutasteride, and oral minoxidil for hair loss after four years of treatment and is considering scalp micropigmentation (SMP). Other users suggest the hair loss pattern may indicate alopecia areata and recommend seeing a dermatologist.

User tried Exosomes for hair loss with no success but experienced healing in other areas. Noticed people with previous hair transplants responded well to Exosomes.

The user is 13 months post-hair transplant and is using 1 mg finasteride and 2.5 mg oral minoxidil. They are seeking opinions on their crown's appearance, considering switching treatments, and contemplating a second transplant due to concerns about hair density and stability.

The conversation is about a user dealing with androgenetic alopecia using minoxidil 5% and attempting to import Adenogen tonic from Japan, which was rejected by Spanish customs. The user seeks advice on obtaining Adenogen or Adenovital within the EU or tips for passing customs.

A user shared progress pictures after 9 years on finasteride and 10 months on oral minoxidil, considering a small FUE hair transplant to fill in temple points. Replies praised the results, suggesting a transplant might not be necessary.

The conclusion of the conversation is that the user has experienced significant hair regrowth using a combination of medications, including dutasteride, RU58841, and minoxidil. They have not experienced any noticeable side effects and are considering a hair transplant in the future.

The user plans to use a "nuclear protocol" for hair improvement, including topical minoxidil 12.5%, topical finasteride 0.1%, and tretinoin 0.05%, with microneedling once a week. They have seen improvements with minoxidil and are seeking opinions on their approach to achieve thicker hair.

The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It highlights an interview with Stemson Therapeutics CEO Geoff Hamilton about advancements in hair cloning technology.

The conversation is about a transgender individual's experience with hair regrowth using topical minoxidil and hormone replacement therapy (HRT), expressing concern about the slow growth and thin appearance of their hair. Some responses encourage patience and highlight the variability of results, while others discuss the role of HRT and its effects.